10 enrolling by invitation. 10 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Enrolling by invitation 10 |
| Phase 1 | 4 | Enrolling by invitation 4 |
Follow Head and Neck Neoplasms: new trials by email Literature Review of Head and Neck Neoplasms trials Research Report on Head and Neck Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients: A Randomized Clinical Trial sirolase xtent laser, blue m gel - Mucositis Oral, Head & Neck Cancer | Phase 1 / Phase 2 | Enrolling by invitation | Assiut University | 46 | 2026-08-15 | 2026-10-08 |
| Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. A single-arm, single-center clinical trial evaluating efficacy - Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Enrolling by invitation | Zhejiang Provincial People's Hospital | 30 | 2026-05-01 | 2026-04-24 |
| BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy Progression Finotonlimab, Cetuximab, Docetaxel - Recurrent Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Enrolling by invitation | Sun Yat-sen University | 42 | 2026-04-20 | 2026-06-01 |
| Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) - Head &Amp; Neck Cancer, Head &Amp; Neck Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | SWOG Cancer Research Network | 50 | 2026-03-25 | 2026-10-05 |
| Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma Nimotuzumab, camrelizumab, Albumin paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Enrolling by invitation | Peking University | 48 | 2025-11-01 | 2025-12-31 |
| Using CICS-1 and SPM-011 and ［18F］FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMA BNCT, ［18F］FBPA - Thoracic Solid Malignant Tumor | Phase 1 / Phase 2 | Enrolling by invitation | Stella Pharma Corporation | 30 | 2025-04-10 | 2025-11-19 |
| IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma IMRT combined with lobaplatin-based concurrent chemotherapy - Nasopharyngeal Neoplasms, Elderly | Phase 2 | Enrolling by invitation | The First Affiliated Hospital of Xiamen University | 32 | 2024-11-13 | 2025-08-07 |
| Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors - Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Man Hu | 100 | 2024-03-30 | 2025-03-30 |
| Oral Herpesviruses and Oral Mucositis in Patients Receiving Head and Neck Radiotherapy Valacyclovir, Placebo - Oral Mucositis, Head and Neck Cancer (H&N) | Phase 2 | Enrolling by invitation | Instituto Oncoclinicas | 84 | 2022-09-05 | 2026-01-23 |
| Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma paclitaxel, carboplatin, tislelizumab - Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | Enrolling by invitation | Qiu Guoqin | 30 | 2022-06-01 | 2024-03-12 |
Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Non-Small-Cell Lung (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2) · Stomatitis (2) · Breast Neoplasms (1) · Glioblastoma (1) · Mesothelioma, Malignant (1) · Nasopharyngeal Neoplasms (1) · Neurofibrosarcoma (1)
Neoplasms (10) · Neoplasms by Site (10) · Neoplasms by Histologic Type (6) · Neoplasms, Glandular and Epithelial (6) · Carcinoma (5) · Carcinoma, Squamous Cell (5) · Digestive System Diseases (4) · Digestive System Neoplasms (4) · Esophageal Diseases (4) · Gastrointestinal Diseases (4) · Gastrointestinal Neoplasms (4) · Stomatognathic Diseases (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2)
Carboplatin (1) · Cetuximab (1) · Cisplatin (1) · Docetaxel (1) · Paclitaxel (1) · Platinum Compounds (1) · Radiotherapy (1) · Radiotherapy, Adjuvant (1) · Valacyclovir (1) · camrelizumab (1) · nimotuzumab (1) · tislelizumab (1)
Assiut University (1) · Instituto Oncoclinicas (1) · Man Hu (1) · Peking University (1) · Qiu Guoqin (1) · SWOG Cancer Research Network (1) · Stella Pharma Corporation (1) · Sun Yat-sen University (1) · The First Affiliated Hospital of Xiamen University (1) · Zhejiang Provincial People's Hospital (1)
China (6) · Brazil (1) · Egypt (1) · Japan (1) · United States (1)
Chunyan Chen, MD, PhD (1) · Jiajie Xu (1) · Man Hu, Dr. (1) · Paul Swiecicki, MD (1) · Xuekui Liu, MD, PhD (1) · Zhihao MM Lu, PHD (1)